Shaping better health
REMEDY : BNSSG referral pathways & Joint Formulary

BNSSG Adult Joint Formulary

COVID-19 rapid evidence summaries

Checked: not set yet by Next Review: not set yet

COVID-19 rapid evidence summaries

Rapid evidence summaries on 2 interleukin-6inhibitors, sarilumab and tocilizumab, in the treatment of adults with COVID-19 have been published.
Preliminary evidence suggests that sarilumab and tocilizumab are beneficial in adults with severe COVID‑19 who are critically ill and receiving respiratory or cardiovascular organ support in an intensive care setting. In adults with less severe COVID‑19 who are not receiving ventilation, evidence is mixed. Any benefit from these drugs may be seen only in the most severely ill patients soon after organ support is started, when any developing organ dysfunction may be more reversible.

New evidence on the effectiveness of COVID-19 treatments is being published at a rapid pace. The evidence reviews for tocilizumab and sarilumab will be updated over the coming weeks in light of emerging evidence.

Also see the following CAS alerts:

CEM CMO 2021 006

Sarilumab Interim Policy

Tocilizumab Interim Policy


The Department of Health and Social Care has published an interim position statement on use of inhaled budesonide for adults 50 years and over with COVID-19.  

 Interim Position Statement: Inhaled budesonide for adults (50 years and over) with COVID-19